Research Article Details

Article ID: A43342
PMID: 31952447
Source: Expert Opin Investig Drugs
Title: Targeting CCR2/5 in the treatment of nonalcoholic steatohepatitis (NASH) and fibrosis: opportunities and challenges.
Abstract:
DOI: 10.1080/13543784.2020.1718106

Strategy ID Therapy Strategy Synonyms Therapy Targets Therapy Drugs
S03 Anti-fibrosis fibrosis Angiotensin Receptor Blocker (ARB); CCR2/CCR5 antagonist; Thyroid receptor β agonist; PEGylated human FGF21 analogue; Monoclonal antibody to lysyl oxidase-like 2 (LOXL2); Galectin-3 inhibitor; FGF19 variant Losartan; Cenicriviroc; VK-2809; MGL-3196; Pegbelfermin; Simtuzumab; GR-MD-02; NGM282 Details

Target ID Target Name GENE Action Class UniProtKB ID Entry Name
T24 C-C chemokine receptor type 2 CCR2 antagonist GPCR P41597 CCR2_HUMAN Details
T25 C-C chemokine receptor type 5 CCR5 antagonist GPCR P51681 CCR5_HUMAN Details

Diseases ID DO ID Disease Name Definition Class

Drug ID Drug Name Type DrugBank ID Targets Category Latest Progress
D068 Cenicriviroc Chemical drug DB11758 CCR2 inhibitor; CCR5 inhibitor Anti-fibrosis Failed in clinical trials Details